{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000015","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.420713+00:00","generated_at":"2026-05-26T04:38:07.756247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Supernus FY 2024 rev $661.8M; Qelbree +72%; ONAPGO approved; SPN-820 Phase 2b fails","bullets":["Full year 2024 revenue $661.8M (+9% YoY); Qelbree net sales $241.3M (+72%) and GOCOVRI $130.8M (+9%).","Full year 2024 operating earnings $81.7M vs loss of $(5.3)M in 2023; adjusted operating earnings $183.7M (+47%).","ONAPGO (apomorphine) FDA approved for advanced Parkinson's; launch planned in Q2 2025.","SPN-820 Phase 2b in treatment-resistant depression failed primary and secondary endpoints; program future under review.","FY 2025 guidance: total revenues $600-630M; adjusted operating earnings $105-130M, down from $183.7M in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000015","json":"https://secwatch.observer/filing/0001356576-25-000015.json","markdown":"https://secwatch.observer/filing/0001356576-25-000015.md","text":"https://secwatch.observer/filing/0001356576-25-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000015/0001356576-25-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000015/supn-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:38:07.756247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}